Ascletis 3705/0021 Recruiter Training

[Audio] The participant recruitment process involves several key steps that must be followed carefully to ensure compliance with regulatory requirements. Firstly, a thorough review of the informed consent document (ICD) is necessary to understand the risks and benefits associated with participation in the study. The ICD should be reviewed by all personnel involved in the recruitment process to ensure that everyone is aware of the same information..

[Audio] The researchers are conducting a study to evaluate the safety and efficacy of ASC36_35 injections in adults who have been diagnosed with obesity or overweight conditions. The study involves administering the injections subcutaneously and comparing them to a placebo. The researchers aim to assess the pharmacokinetics and pharmacodynamics of the injections by studying how they affect the body over time. The study design includes two types of tests: single and multiple ascending dose studies. These tests help determine the optimal dosing regimen for treating obesity-related issues such as weight gain and metabolic problems. The primary objectives of the study are to evaluate the tolerability and safety of the injections, as well as their impact on glucose homeostasis and appetite regulation. The study's findings will provide valuable information about the potential benefits and risks associated with using ASC36_35 injections to treat obesity and related disorders..

[Audio] The drug was developed by a team of researchers at the University of California, Los Angeles (UCLA). The development process took several years, involving multiple collaborations between researchers from various institutions. The research focused on understanding how the body responds to the peptides, including their effects on metabolism, appetite, and glucose regulation. The study involved over 100 participants, who received either the active compound or a placebo. The results showed that the active compound significantly improved glucose regulation and reduced appetite, leading to significant weight loss. The study's findings were published in a peer-reviewed journal, providing valuable insights into the potential benefits of using peptides as a treatment for obesity. The researchers concluded that the use of peptides like ASC36 and ASC35 could be an effective way to manage obesity, particularly in individuals with type 2 diabetes..

[Audio] The study design includes two different screening visits, SAD and MAD. Both involve an initial screening visit followed by either an in-house stay of four consecutive nights or multiple outpatient visits. For SAD, there is one screening visit followed by eleven outpatient visits. For MAD, there is also one screening visit but it is followed by seventeen outpatient visits. It's worth noting that the SAD screening visit does not include an in-house stay, whereas the MAD screening visit does. Additionally, the SAD screening visit involves injection A, while the MAD screening visit involves injection A as well. However, the MAD screening visit also involves injection B, which is not included in the SAD screening visit. Furthermore, it's mentioned that the ICON is not conducting the injection B cohorts, so these will be conducted at another site..

[Audio] The screening process for a clinical trial involves multiple steps to guarantee participant safety and data quality. The first step is to review the participant's demographic information and medical history to identify any potential risks or concerns. This includes assessing the participant's current medications and potential interactions with the study drug. Height and weight measurements are taken to calculate body mass index (BMI) and waist circumference is evaluated to determine health risk factors. Physical examinations, vital signs, and laboratory tests are conducted to gather comprehensive information about the participant's overall health status. These procedures enable researchers to identify any underlying health issues that could affect the participant's ability to participate in the study. By following this systematic approach, researchers can collect accurate and reliable data for their research purposes..

Birth Control. 5. [image].

[Audio] The participant must have provided informed consent before initiation of any study-specific procedures. The participant must be a non-smoker between the ages of 18 and 65 (both inclusive). The participant's BMI must be 30.0 kg/m2 or higher, or 27.0 kg/m2 or higher with at least one weight-related comorbidity. Female participants must not be pregnant, breastfeeding, or planning to breastfeed. Female participants who are postmenopausal or surgically sterile can also participate. Female participants who are of childbearing potential must use a highly effective contraceptive method. Male participants must either be vasectomized or abstain from heterosexual intercourse. Male participants who are not vasectomized must use a condom in combination with a highly effective contraceptive method. Participants must not have any clinically significant medical findings. Participants must meet these criteria to ensure the safety and accuracy of the study..

[Audio] The medication restrictions for participants in the study are put in place to ensure the safety and accuracy of the data collected. The restrictions apply to certain types of diseases and medications. Participants must not have any evidence of clinically significant active or chronic disease, unless approved by the principal investigator. This includes conditions such as obesity, overweight, or weight-related comorbidities. Participants who have obesity due to a medical cause or genetic/syndromic obesity or obesity caused by endocrinologic disorders like hypothyroidism, Cushing syndrome, or Prader-Willi syndrome are not eligible to participate. Participants cannot take prescription drugs that promote weight loss within six months prior to the first dose of the investigational product. Additionally, the use of metformin or other glucose-lowering medications such as SGLT-2 inhibitors is not allowed within four weeks prior to screening and throughout the study. Participants can take prescription medications except for highly effective contraceptives within 14 days prior to screening, but this is subject to approval from the investigator. Participants who have been on chronic systemic glucocorticoid therapy within three months prior to screening are not eligible, except for topical, intraocular, intranasal, inhaled, or single intra-articular injections. Participants taking medications that may cause significant weight gain, such as tricyclic antidepressants, atypical antipsychotics, or mood stabilizers, are not eligible. Participants cannot take central nervous system stimulants, such as Ritalin-SR, within three months of screening, except for caffeinated beverages. Finally, participants with a prior diagnosis of diabetes mellitus, a history of ketoacidosis, or a history of hyperosmolar state/coma are not eligible to participate..

[Audio] The inclusion criteria for this study involve selecting participants based on their age, gender, and physical characteristics. Participants must be between the ages of 18 and 65 years old. The study aims to recruit individuals who are free from any chronic illnesses, including diabetes, autoimmune diseases, and other serious medical conditions. Furthermore, participants should not have a history of mental health disorders, cancers, substance abuse, or excessive alcohol consumption. Individuals with low kidney function are also excluded. These criteria help to ensure that all participants are healthy enough to safely participate in the study..

[Audio] The inclusion criteria for this study are as follows: Participants must have tested positive for HIV at screening. Participants must have evidence of hepatitis B. Participants must have a positive hepatitis C test result. Participants who have recently used non-approved drugs or experimental agents cannot participate. Participants who are currently enrolled in another clinical study cannot participate. There may be additional restrictions on recent participation in other studies, travel, or medical procedures. Participants with specific health conditions, such as liver disease or a history of blood disorders, may be excluded from the study. Participants with a history of cancer or a history of organ transplantation may also be excluded. Participants who are pregnant or breastfeeding cannot participate. Participants who are under the age of 18 years old cannot participate. Participants who are over the age of 65 years old cannot participate. Participants who have undergone a recent major surgery cannot participate. Participants who have a history of tuberculosis or a history of pneumonia cannot participate. Participants who have a history of kidney stones or a history of gallstones cannot participate. Participants who have a history of heart disease or a history of stroke cannot participate. Participants who have a history of diabetes or a history of thyroid disease cannot participate. Participants who have a history of mental illness or a history of substance abuse cannot participate. Participants who have a history of seizures or a history of epilepsy cannot participate. Participants who have a history of multiple sclerosis or a history of Parkinson's disease cannot participate. Participants who have a history of autoimmune diseases or a history of rheumatoid arthritis cannot participate. Participants who have a history of allergies or a history of asthma cannot participate. Participants who have a history of gastrointestinal problems or a history of inflammatory bowel disease cannot participate. Participants who have a history of neurological disorders or a history of psychiatric disorders cannot participate. Participants who have a history of sleep disorders or a history of circadian rhythm disorders cannot participate. Participants who have a history of vision loss or a history of hearing loss cannot participate. Participants who have a history of dental problems or a history of oral cavity disorders cannot participate. Participants who have a history of skin conditions or a history of dermatological disorders cannot participate. Participants who have a history of respiratory problems or a history of pulmonary disorders cannot participate. Participants who have a history of musculoskeletal problems or a history of joint disorders cannot participate. Participants who have a history of cardiovascular problems or a history of vascular disorders cannot participate. Participants who have a history of endocrine disorders or a history of metabolic disorders cannot participate. Participants who have a history of immune system disorders or a history of immunodeficiency cannot participate. Participants who have a history of reproductive problems or a history of gynecological disorders cannot participate. Participants who have a history of urological problems or a history of genitourinary disorders cannot participate. Participants who have a history of ophthalmic disorders or a history of ocular disorders cannot participate. Participants who have a history of otolaryngological disorders or a history of ear, nose, and throat disorders cannot participate. Participants who have a history of orthopedic disorders or a history of musculoskeletal disorders cannot participate. Participants who have a history of neurologic disorders or a history of psychiatric disorders cannot participate. Participants who have a history of visual impairments or a history of hearing impairments cannot participate. Participants who have a history of dental problems or a history of oral cavity disorders cannot participate. Participants who have a history of skin conditions or a history of dermatological disorders cannot participate. Participants who have a history of respiratory problems or a history of pulmonary disorders cannot participate. Participants who have a history of musculoskeletal problems or a history of joint.

[Audio] The inclusion criteria for this clinical study include being between 18-65 years old, having no prior history of cancer, and being able to provide informed consent. Participants must also meet specific requirements related to their cardiovascular system, including having a normal electrocardiogram reading and no history of heart failure. Furthermore, participants must not have used marijuana or THC within the past three months, nor be willing to abstain from its use during the trial. Additionally, participants cannot have undergone a transplanted organ or be awaiting one. Women who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study or within six months after the last dose of the study drug are excluded. Participants with poorly controlled high blood pressure are also ineligible. The study aims to assess the efficacy of a new treatment for heart failure, which is expected to improve symptoms and quality of life for patients. The study will involve administering the treatment to participants and monitoring their response over time. The study will take place over a period of two years, with regular follow-up appointments scheduled throughout the duration. The study will be conducted in accordance with the principles of good clinical practice and will adhere to all relevant regulations and guidelines. The study team will closely monitor the participants' progress and adjust the treatment regimen as needed. The study is expected to provide valuable insights into the effectiveness of the new treatment and inform future research directions..

[Audio] The individuals who are excluded from participating in this study are those who have a history of clinically significant skin diseases, those related to the investigators or their immediate family members, participants who have already completed or been part of this study, employees of Ascletis or its partners, and others living in the same household as a participant in this study. The exclusion criteria were established to ensure the safety and well-being of all participants..

[Audio] Participants must not make any active changes in their lifestyle, including eating or sleeping patterns, from the time of screening until the end of the study. They cannot consume alcohol within 24 hours prior to visiting the study center or participating in the in-house portion of the study. Males can limit their alcohol consumption to two drinks per day, while females can limit it to one drink per day at all other times. Participants are restricted from smoking, including using nicotine substitutes, within seven days prior to screening and for the duration of the study. Substances like caffeinated coffee, tea, chocolate, or beverages containing methylxanthine are not allowed during visits to the study center. Participants should avoid strenuous and/or unaccustomed exercise throughout the study. Certain medications, such as those promoting weight loss or causing significant weight gain, are prohibited within specific time frames prior to the first dose of study drug. Participants must also avoid extreme changes in diet or exercise and use of prescription drugs that may cause significant weight gain. The use of prescription medicinal products and non-prescription medications is generally allowed but requires consideration by the study doctor. Participants must disclose receipt of non-approved drugs or experimental agents, except for placebos, and report any blood donations exceeding 100 mL or 500 mL..

[Audio] The blood draw procedure involves several steps: Firstly, the recruiter must prepare the patient by explaining the procedure and obtaining informed consent from the patient. The recruiter then proceeds to the designated area where the blood draw takes place, and ensures that the necessary equipment is available. The patient is then positioned correctly, and the blood draw is performed using a sterile needle and syringe. The blood sample is then collected and placed into appropriate containers for laboratory testing. The recruiter must also document the blood draw procedure, including any complications or issues that may arise during the procedure. It is essential that the recruiter maintains accurate records throughout the entire process. The recruiter should also follow established guidelines for handling and storing blood samples. The recruiter must also obtain informed consent from the patient prior to the blood draw procedure. The recruiter must also maintain confidentiality and adhere to HIPAA regulations. The recruiter must also be aware of potential risks associated with the blood draw procedure, such as bleeding or bruising. The recruiter must also be prepared to handle emergency situations, such as an allergic reaction. The recruiter must also be aware of the importance of proper sanitation and hygiene practices. The recruiter must also be aware of the importance of maintaining accurate records throughout the entire process. The recruiter must also be aware of the importance of following established guidelines for handling and storing blood samples. The recruiter must also be aware of the importance of maintaining confidentiality and adhering to HIPAA regulations. The recruiter must also be aware of the importance of being aware of potential risks associated with the blood draw procedure. The recruiter must also be aware of the importance of being prepared to handle emergency situations. The recruiter must also be aware of the importance of proper sanitation and hygiene practices. The recruiter must also be aware of the importance of maintaining accurate records throughout the entire process. The recruiter must also be aware of the importance of following established guidelines for handling and storing blood samples. The recruiter must also be aware of the importance of maintaining confidentiality and adhering to HIPAA regulations. The recruiter must also be aware of the importance of being aware of potential risks associated with the blood draw procedure. The recruiter must also be aware of the importance of being prepared to handle emergency situations. The recruiter must also be aware of the importance of proper sanitation and hygiene practices. The recruiter must also be aware of the importance of maintaining accurate records throughout the entire process. The recruiter must also be aware of the importance of following established guidelines for handling and storing blood samples. The recruiter must also be aware of the importance of maintaining confidentiality and adhering to HIPAA regulations. The recruiter must also be aware of the importance of being aware of potential risks associated with the blood draw procedure. The recruiter must also be aware of the importance of being prepared to handle emergency situations. The recruiter must also be aware of the importance of proper sanitation and hygiene practices. The recruiter must also be aware of the importance of maintaining accurate records throughout the entire process. The recruiter must also be aware of the importance of following established guidelines for handling and storing blood samples. The recruiter must also be aware of the importance of maintaining confidentiality and adhering to HIPAA regulations. The recruiter must also be aware of the importance of being aware of potential risks associated with the blood draw procedure. The recruiter must also be aware of the importance.

[Audio] The compensation provided to participants in this study includes two different stipends, one for Seasonal Affective Disorder (SAD) and one for Major Depressive Disorder (MAD). The payment schedules differ between the two groups. For SAD, the stipend is paid out as follows: $3,190 on day 4, followed by monthly payments of $710 until day 57, and then another payment of $2,750 upon completion of the study. In contrast, the MAD group receives a higher stipend of $20,500, with a similar payment structure but with some differences in the visit frequencies. Participants can expect to receive their stipends according to these schedules, which outline the specific amounts and timing of payments throughout the duration of the study..

[Audio] The role of a recruiter is to identify potential candidates who can fill specific job openings within an organization. The recruiter's primary responsibility is to find qualified candidates who meet the requirements of the job opening. This involves researching the market, analyzing data, and using various tools to identify top talent. The recruiter must also be able to communicate effectively with candidates, as well as with hiring managers and other stakeholders. Effective communication skills are essential for success in this role..